ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Rhea-AI Summary

ChromaDex Corp. (NASDAQ: CDXC), a leader in NAD+ research and healthy aging science, has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit. The virtual event will feature a company presentation scheduled for Monday, January 13, 2025, at 12:00 p.m. ET.

Investors can access the webcast directly through Lytham Partners' dedicated event page or the conference homepage. A replay option will be available following the presentation. Additionally, one-on-one investor meetings can be arranged through Lytham representatives or by contacting Ben Shamsian, Vice President at Lytham Partners, who serves as ChromaDex's investor relations contact.

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at https://lythampartners.com/health2025/cdxc or by visiting the conference home page at https://lythampartners.com/health2025/. A replay of the presentation will also be available through the same links.

1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at 1x1@lythampartners.com or ChromaDex’s investor relations contact, Ben Shamsian, Vice President at Lytham Partners, at shamsian@lythampartners.com or 646-829-9701.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen^® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen^®, the number one healthy-aging NAD+ supplement in the United States^†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex supplies pharmaceutical-grade Niagen^® to U.S. FDA-registered 503B outsourcing facilities, which compound and distribute intravenous and injectable Niagen^® for clinics. These pharmaceutical-grade Niagen^® products, known as Niagen IV and Niagen injections, are available exclusively at clinics with a prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106447116/en/

ChromaDex Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Ben Shamsian

Lytham Partners

646-829-9701

shamsian@lythampartners.com

Source: ChromaDex Corporation

FAQ

When is ChromaDex (CDXC) presenting at the Lytham Partners 2025 Healthcare Summit?

ChromaDex (CDXC) will present at the Lytham Partners 2025 Healthcare Summit on Monday, January 13, 2025, at 12:00 p.m. ET.

How can investors access ChromaDex's (CDXC) presentation at the Lytham Partners Summit?

Investors can access the webcast directly at lythampartners.com/health2025/cdxc or through the conference homepage at lythampartners.com/health2025/.

Will there be a replay available of ChromaDex's (CDXC) Lytham Partners presentation?

Yes, a replay of ChromaDex's presentation will be available through the same webcast links after the live event.

How can investors schedule 1x1 meetings with ChromaDex (CDXC) management?

Investors can schedule 1x1 meetings by contacting their Lytham representative at 1x1@lythampartners.com or reaching out to Ben Shamsian at shamsian@lythampartners.com or 646-829-9701.